Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Sellas Life Sciences Group Inc SLS

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor... see more

Bullboard (NDAQ:SLS)

View:
User Avatar Image
(63)
•••
  • IseneschalX
Post by Iseneschalon Nov 13, 2023 8:53am

SLS....NR bump

FDA mentioned....$1.04
User Avatar Image
(144)
•••
  • unclepiemanX
Comment by unclepiemanon Dec 30, 2020 3:29pm

RE:225 $

lol what nonsense pump. did you write your nonsense and then take off? haha
User Avatar Image
(668)
•••
  • coolfooldumbguyX
Post by coolfooldumbguyon Feb 26, 2020 12:16pm

still holding this stock

from last year,it did a reverse split,but it's trying to make a comeback,so glta shareholders.
User Avatar Image
(4)
•••
  • kwhistler64X
Post by kwhistler64on Dec 02, 2019 10:08am

Breaking News

https://jhoponline.com/ton-web-exclusives/17423-sellas-announces-promising-data-on-neuvax-in-combination-with-herceptin-in-her2-1-2-breast-cancer-jhop
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >